Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Status:
Recruiting
Trial end date:
2027-03-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate pathological complete response (pCR) rate of
coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded
central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC)
[Cohort A] and to evaluate lenvatinib in combination with coformulated
favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in
participants proficient in mismatch repair (pMMR) endometrial cancer (EC) [Cohort B].